Combination therapy for the treatment of multiple sclerosis: challenges and opportunities

References

• Blevins G, Martin R. Future immunotherapies in multiple sclerosis. Semin Neurol 2003;23:147–57
   PubMed Web of Science ®Google Scholar
• Confavreux C. Combination therapies. In: Rudick RA, Goodkin DE, editors. Multiple sclerosis therapeutics. London: Martin Dunitz; 1999. p. 395–403
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–94
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504
   Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655–61
   Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing1–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268–76
   PubMed Web of Science ®Google Scholar
• Freedman MS, Patry DG, Grand’Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31: 157–168
   Google Scholar
• International Working Group for Treatment Optimization in MS. Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2004;11:43–7
   PubMed Web of Science ®Google Scholar
• Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002;162:2161–9
   Google Scholar
• Kaufman M. Combining therapies with interferon beta for relapsing and early progressive MS: a review. Int J MS Care 2002;4:50–65
   Google Scholar
• Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. New Engl J Med 1993;329:1764–9
   PubMed Web of Science ®Google Scholar
• Richert ND, Ostuni JL, Bash CN, et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001;7:49–58
   PubMed Web of Science ®Google Scholar
• Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000;247:435–42
   PubMed Web of Science ®Google Scholar
• Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNβ-1b. Neurology 2002;59:688–94
   PubMed Web of Science ®Google Scholar
• Gasperini C, Pozzilli C, Bastianello S, et al. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998;50:403–6
   PubMed Web of Science ®Google Scholar
• Barkhof F, Frequin ST, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63–7
   PubMed Web of Science ®Google Scholar
• Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450–3
   PubMed Web of Science ®Google Scholar
• Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219–22
   PubMed Web of Science ®Google Scholar
• Burnham JA, Wright RR, Dreisbach J, Murray RS. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991;41:1349–54
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing–remitting MS. Neurology 2001;57:1239–47
   PubMed Web of Science ®Google Scholar
• Havrdova E, Zivadinov R, Krasensky J, et al. Efficacy results from a randomized, double-blind, placebo-controlled study of intramuscular interferon beta 1-a, azathioprine corticosteroid combination therapy in patients with relapsing–remitting multiple sclerosis. Mult Scler 2006;12\(Suppl 1):S11 [abstract 61]
   Google Scholar
• Moreau T, Blanc S, Riche G, et al. A pilot safety and tolerability study of interferon beta 1a in combination with azathioprine in multiple sclerosis. Neurology 2001;56\(Suppl 3):A353 [abstract P05.099]
   Google Scholar
• Kolar OJ, Huler KK, Muckway MA. Continuous combined immunomodulatory-immunosuppressive (IMIS) therapy in multiple sclerosis (MS). Mult Scler 1999;5\(Suppl 1):S95 [abstract P371]
   Google Scholar
• Moreau T, Blanc S, Riche G, Confavreux C. ERAZIMUS: combination of azathioprine and beta-interferon in multiple sclerosis: results of a pilot safety study. Mult Scler 1999;5\(Suppl 1):S95 [abstract P372]
   Google Scholar
• Fernández O, Guerrero M, Mayorga C, et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis: a two-year pilot study. J Neurol 2002;249: 1058–62
   Google Scholar
• Lus G, Romano F, Scuotto A, et al. Azathioprine and interferon β1a in relapsing–remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 2004;51:15–20
   PubMed Web of Science ®Google Scholar
• Patti F, Reggio E, Fiorilla T, et al. Rapidly transitional multiple sclerosis patients treated with combination of cyclophosphamide and interferon beta: follow-up 36 months after discontinuation of therapy. Neurology 2003;60\(Suppl 1):A148-A149 [abstract P02.132]
   Google Scholar
• Patti F, Cataldi ML, Nicoletti F, et al. Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:404–7
   PubMed Web of Science ®Google Scholar
• Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573–82
   PubMed Web of Science ®Google Scholar
• Kaufman M, Norton HJ, Sonnenfeld G. A randomized controlled safety trial of interferon beta-1a and oral cyclophosphamide in MS. Int J MS Care [serial on-line] 2002;4
   Google Scholar
• Kaufman M, Norton J, Sonnenfeld G. Safety and tolerability of the combination of interferon beta-1a and oral cyclophosphamide for patients with multiple sclerosis. Neurology 2001;56\(Suppl 3):A354 [abstract P05.101]
   Google Scholar
• Rowe VD, Wang D, John HA, et al. Rescue therapy with high dose intravenous methotrexate in MS patients worsening despite Avonex therapy. Neurology 2003;60\(Suppl 1):A149-A150 [abstract P02.135]
   Google Scholar
• Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS. Neurology 2002;58:314–7
   PubMed Web of Science ®Google Scholar
• Whartenby KA, Mills PC, Rogg J, et al. An open label trial of combination MS therapy using IFN β1a and oral methotrexate 20 mg weekly. Neurology 2000;54\(Suppl 3):A24 [abstract S11.005]
   Google Scholar
• Jain KK. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Investig Drugs 2000;9:1139–49
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, Morrissey S, et al. Mitoxantrone. In: Rudick RA, Goodkin DE, editors. Multiple sclerosis therapeutics. London: Martin Dunitz; 1999. p. 335–48
   Google Scholar
• Novantrone (mitoxantrone for injection concentrate) [package insert]. Rockland (MD): Serono, Inc.; 2005
   Google Scholar
• Jeffery DR, Chepuri N, Durden D, et al. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 2005;11:296–301
   PubMed Web of Science ®Google Scholar
• Le Page E, Leray E, Debouverie M, et al. Induction treatment with mitoxantrone in worsening relapsing remitting multiple sclerosis: a ‘rescue therapy’ for sub-optimal responders to interferon beta? A pilot study. Neurology 2003;60\(Suppl 1): A149 [abstract P02.133]
   Google Scholar
• Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995;61:185–93
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S, Chen M, Henschel K, et al. Effect of combined IFNβ-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 2002;8: 485–91
   Google Scholar
• Zang Y, Hong J, Robinson R, et al. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol 2003;137:144–53
   PubMed Web of Science ®Google Scholar
• Lublin F, Baier M, Cutter G, et al. Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate. Neurology 2002;58\(Suppl 3): A85 [abstract S13.003]
   Google Scholar
• Lublin F, Cutter G, Elfont R, et al. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS. Neurology 2001;56(Suppl):A148 [abstract S20.002]
   Google Scholar
• Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004;27:80–3
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006;354:899–910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med 2006;354:911–23
   PubMed Web of Science ®Google Scholar
• Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. New Engl J Med 2005;353:432–3
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. New Engl J Med 2005;353: 369–74
   Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. New Engl J Med 2005;353:375–81
   Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. New Engl J Med 2005;353:362–8
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl J Med 2006;354:924–33
   PubMed Web of Science ®Google Scholar
• Tysabri [package insert]. Cambridge (MA): Biogen Idec Inc.; 2006
   Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New Engl J Med 2006;355:1124–40
   PubMed Web of Science ®Google Scholar
• Cohen JA, Calabresi PA, Fisher E, et al. Rationale, design, and baseline data for the Avonex Combination Trial. Mult Scler 2005;11\(Suppl 1):S155 [abstract P588]
   Google Scholar
• Clinicaltrials.gov. Combination therapy in patients with relapsing–remitting multiple sclerosis (MS). Available at: http://www.clinicaltrials.gov/ct/show/NCT00211887?order=1 [last accessed 10 January 2007]
   Google Scholar
• Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112–8
   PubMed Web of Science ®Google Scholar
• American Society of Health-System Pharmacists. AHFS drug handbook. Springhouse (PA): Lippincott Williams and Wilkins; 2003
   Google Scholar
• National Multiple Sclerosis Society. Clinical trials in multiple sclerosis: fall/winter 2005: planned, in progress, recently completed. Available at: http://www.nationalmssociety.org/pdf/ research/clinicaltrials.pdf [last accessed 15 December 2005]
   Google Scholar